Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology · Wild-Type Transthyretin Amyloidosis

Connecting the Dots: Symptoms and Warning Signs

At a Glance

Wild-type ATTR amyloidosis (wtATTR) follows a predictable symptom timeline. Early warning signs like bilateral carpal tunnel syndrome and spinal stenosis typically appear 5 to 15 years before the disease causes stiffening of the heart muscle and classic heart failure symptoms.

For many people with wild-type transthyretin amyloidosis (wtATTR), the diagnosis feels like the final piece of a puzzle that has been forming for a decade. While the heart symptoms are often what lead to a diagnosis, they are usually preceded by a series of “red flag” warning signs in other parts of the body [1][2].

Understanding this timeline can help you realize that what you’ve been experiencing isn’t just “getting older”—it is a recognizable pattern of a specific medical condition.

The Orthopedic “Early Warning” Phase

One of the most striking features of wtATTR is how often it affects the joints and spine years before it affects the heart. These symptoms occur because the unstable TTR protein often deposits in ligaments and tendons first [3][4].

  • Bilateral Carpal Tunnel Syndrome: This is often the very first sign. Up to 50% of patients with wtATTR have a history of carpal tunnel in both hands [5][6]. Crucially, this typically happens 5 to 15 years before any heart problems appear [6][7].
  • Lumbar Spinal Stenosis: This involves a narrowing of the lower spinal canal, often caused by the thickening of a ligament (the ligamentum flavum) due to amyloid deposits [8][3].
  • The “Popeye Sign”: This is a spontaneous rupture of the biceps tendon, which creates a visible bulge in the upper arm [9][10]. If this happened to you without a major injury, it is a strong “red flag” for wtATTR.

Cardiac Symptoms: Restrictive Cardiomyopathy

When the amyloid fibrils begin to build up in the heart muscle, they cause restrictive cardiomyopathy [11]. This means the heart walls become thick and “stiff,” making it hard for the heart to relax and fill with blood [12]. This leads to symptoms of heart failure, such as:

  • Shortness of Breath: Initially during exercise, but eventually while resting [2].
  • Fluid Retention: Swelling in the legs (edema), ankles, or even the abdomen [2][13].
  • Fatigue and Dizziness: Because the heart is too stiff to pump enough oxygen-rich blood to the body.

How it Differs from Common Heart Failure

wtATTR is frequently misdiagnosed as typical HFpEF (Heart Failure with Preserved Ejection Fraction) caused by high blood pressure [11][12]. However, wtATTR has unique features your doctor may look for:

  • Apical Sparing: On a specialized ultrasound (echocardiogram), the bottom of the heart (the apex) often continues to move normally while the rest of the heart is stiff. This happens because the amyloid proteins tend to deposit less at the very tip of the heart compared to the upper walls, creating this unique “red flag” imaging pattern [14][15].
  • High Biomarkers: Patients with wtATTR often have chronically elevated levels of heart stress markers (like Troponin and NT-proBNP) that are higher than expected for their level of symptoms [16][17].

Neuropathy in wtATTR

While severe nerve damage is more common in the hereditary form of the disease, patients with the wild-type form can also develop peripheral neuropathy [18][19]. You may experience:

  • Sensory Changes: Numbness, tingling, or a “pins and needles” sensation, usually starting in the toes and feet [20][21].
  • Slow Progression: Unlike some other nerve conditions, the neuropathy in wtATTR tends to be slow and steady [18].
  • Autonomic Issues: In more advanced stages, you might notice issues with digestion, bladder control, or feeling lightheaded when standing up [22][23].

Recognizing these symptoms as a unified condition is the first step toward getting the specific treatments that address the root cause of the protein misfolding.

Return to Home | Next: Diagnosis and Avoiding Misdiagnosis

Common questions in this guide

How is carpal tunnel syndrome related to wtATTR?
Up to half of patients with wild-type ATTR amyloidosis develop carpal tunnel syndrome in both hands. This occurs because amyloid proteins frequently deposit in wrist ligaments first, often 5 to 15 years before any heart symptoms appear.
Why is wild-type ATTR amyloidosis often misdiagnosed as regular heart failure?
The amyloid buildup makes the heart muscle thick and stiff, a condition called restrictive cardiomyopathy. This closely mimics the symptoms of typical heart failure caused by high blood pressure, leading to frequent misdiagnosis.
What does apical sparing mean on an echocardiogram?
Apical sparing is a unique pattern seen on an echocardiogram where the bottom tip of the heart moves normally while the rest of the heart wall remains stiff. This imaging pattern is considered a strong red flag for cardiac amyloidosis.
What is the Popeye sign in amyloidosis?
The Popeye sign refers to a spontaneous rupture of the biceps tendon that creates a visible bulge in the upper arm. If this happens without a major physical injury, it is a significant warning sign for wtATTR.
Can wild-type ATTR amyloidosis cause nerve damage in my feet?
Yes, some patients with the wild-type form of the disease develop peripheral neuropathy. This typically presents as a slow, steady progression of numbness, tingling, or a pins-and-needles sensation starting in the feet.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my history of carpal tunnel and spinal stenosis, how likely is it that my heart failure is actually wtATTR?
  2. 2.Do my echocardiogram results show 'apical sparing' or other patterns typical of amyloidosis?
  3. 3.Are my cardiac biomarker levels (Troponin and NT-proBNP) higher than you would expect for typical heart failure?
  4. 4.How does the presence of peripheral neuropathy (the numbness in my feet) change my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).

    Ladefoged B, Clemmensen T, Dybro A, et al.

    ESC heart failure 2023; (10(1)):234-244 doi:10.1002/ehf2.14173.

    PMID: 36193570
  2. 2

    Case Report and Literature Review of Cardiac Amyloidosis: A Not-So-Rare Cause of Heart Failure.

    Baptista P, Moura de Azevedo S, Alexandre A, Dias-Frias A

    Cureus 2023; (15(1)):e33364 doi:10.7759/cureus.33364.

    PMID: 36751253
  3. 3

    Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels.

    George KM, Hernandez NS, Breton J, et al.

    Clinical neurology and neurosurgery 2021; (206()):106708 doi:10.1016/j.clineuro.2021.106708.

    PMID: 34053807
  4. 4

    Association Between Occupational Physical Work Exposure and Wild-Type Transthyretin Cardiomyopathy.

    Ladefoged BT, Olesen KK, Maeng M, Poulsen SH

    JACC. Advances 2026; (5(3)):102619 doi:10.1016/j.jacadv.2026.102619.

    PMID: 41734414
  5. 5

    Characteristics of Carpal Tunnel Syndrome in Wild-Type Transthyretin Amyloidosis.

    Russell A, Khayambashi S, Fine NM, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2024; (51(4)):482-486 doi:10.1017/cjn.2023.268.

    PMID: 37555238
  6. 6

    Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.

    Nakagawa M, Sekijima Y, Yazaki M, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2016; (23(1)):58-63 doi:10.3109/13506129.2015.1135792.

    PMID: 26852880
  7. 7

    Peripheral neuropathy symptoms in wild type transthyretin amyloidosis.

    Wajnsztajn Yungher F, Kim A, Boehme A, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(3)):265-272 doi:10.1111/jns.12403.

    PMID: 32627282
  8. 8

    Cardiac amyloidosis after lumbar spinal stenosis surgery - a comprehensive prospective cohort study.

    Eldhagen P, Tzortzakakis A, Lund LH, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(3)):218-225 doi:10.1080/13506129.2025.2481310.

    PMID: 40134205
  9. 9

    Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.

    Geller HI, Singh A, Alexander KM, et al.

    JAMA 2017; (318(10)):962-963 doi:10.1001/jama.2017.9236.

    PMID: 28898370
  10. 10

    Clinical characteristics and prognostic implications of orthopedic ligament disorders in patients with wild-type transthyretin amyloidosis cardiomyopathy.

    Klarskov VR, Ladefoged BT, Pedersen ALD, et al.

    Journal of cardiology 2023; (82(2)):122-127 doi:10.1016/j.jjcc.2023.04.019.

    PMID: 37141937
  11. 11

    Cardiac amyloidosis: An underdiagnosed/underappreciated disease.

    Manolis AS, Manolis AA, Manolis TA, Melita H

    European journal of internal medicine 2019; (67()):1-13 doi:10.1016/j.ejim.2019.07.022.

    PMID: 31375251
  12. 12

    Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.

    Eldhagen P, Berg S, Lund LH, et al.

    Journal of internal medicine 2021; (289(6)):895-905 doi:10.1111/joim.13222.

    PMID: 33274477
  13. 13

    Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy.

    Schwarting SK, Bieber T, Davies DR, et al.

    Circulation. Heart failure 2025; (18(4)):e011796 doi:10.1161/CIRCHEARTFAILURE.124.011796.

    PMID: 39963776
  14. 14

    Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study?

    Shen CP, Vanichsarn CT, Pandey AC, et al.

    The international journal of cardiovascular imaging 2023; (39(1)):201-208 doi:10.1007/s10554-022-02692-y.

    PMID: 36598681
  15. 15

    Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.

    Tanaka H

    International journal of cardiology 2026; (450()):134245 doi:10.1016/j.ijcard.2026.134245.

    PMID: 41698549
  16. 16

    High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.

    De Michieli L, Sinigiani G, Guida G, et al.

    Circulation. Heart failure 2025; (18(8)):e012816 doi:10.1161/CIRCHEARTFAILURE.125.012816.

    PMID: 40371473
  17. 17

    Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.

    Law S, Petrie A, Chacko L, et al.

    Heart (British Cardiac Society) 2022; (108(6)):474-478 doi:10.1136/heartjnl-2021-319063.

    PMID: 33990410
  18. 18

    Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.

    Živković SA, Lacomis D, Soman P

    Frontiers in cardiovascular medicine 2024; (11()):1345608 doi:10.3389/fcvm.2024.1345608.

    PMID: 38410247
  19. 19

    Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.

    Kleefeld F, Scherret E, Knebel F, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(2)):92-101 doi:10.1080/13506129.2021.2014448.

    PMID: 34994254
  20. 20

    Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

    Chiaro G, Stancanelli C, Koay S, et al.

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.

    PMID: 38769233
  21. 21

    Polyneuropathy in Wild-Type Transthyretin Amyloidosis.

    Sciarrone MA, Vitali F, Guglielmino V, et al.

    European journal of neurology 2025; (32(11)):e70374 doi:10.1111/ene.70374.

    PMID: 41190570
  22. 22

    Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study.

    Hussain Y, Malhotra S, Sperry BW, et al.

    Annals of medicine 2025; (57(1)):2537347 doi:10.1080/07853890.2025.2537347.

    PMID: 40974604
  23. 23

    Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy.

    Sander L, Chiaro G, Abelardo D, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(3)):246-254 doi:10.1080/13506129.2025.2494657.

    PMID: 40275642

This page provides educational information on the symptoms and timeline of wtATTR. It is not a substitute for professional medical evaluation by a cardiologist or specialist. Always consult your healthcare provider for an accurate diagnosis.

Get notified when new evidence is published on Wild type ATTR amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.